The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Lipocine Inc.’s LPCN 1148 as a treatment for sarcopenia in patients with decompensated cirrhosis.   LPCN 1148, an oral prodrug of bioidentical testosterone, was recently studied in a proof-of-concept (POC) Phase 2 study in patients with decompensated cirrhosis.  Treatment with LPCN 1148 in the POC study improved sarcopenia and associated clinical outcomes.  LPCN 1148 is targeted to be a “First in Class&#822...